← Back to home

Advanced malignancies with homologous recombination deficiency (HRD) (breast, ovarian, MCRPC, brain metastases)

Clinical trials for Advanced malignancies with homologous recombination deficiency (HRD) (breast, ovarian, MCRPC, brain metastases) explained in plain language.

Never miss a new study

Get alerted when new Advanced malignancies with homologous recombination deficiency (HRD) (breast, ovarian, MCRPC, brain metastases) trials appear

Sign up with your email to follow new studies for Advanced malignancies with homologous recombination deficiency (HRD) (breast, ovarian, MCRPC, brain metastases), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New drug DSB2455 targets Hard-to-Treat cancers in early trial

Disease control Recruiting now

This early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…

Matched conditions: ADVANCED MALIGNANCIES WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) (BREAST, OVARIAN, MCRPC, BRAIN METASTASES)

Phase 1 • Sponsor: Duke Street Bio Ltd • Aim: Disease control

Last updated Sep 04, 2026 00:00 UTC

Advanced malignancies with homologous recombination deficiency (HRD) (breast, ovarian, MCRPC, brain metastases)

Get alerted when new Advanced malignancies with homologous recombination deficiency (HRD) (breast, ovarian, MCRPC, brain metastases) trials appear

New drug DSB2455 targets Hard-to-Treat cancers in early trial